Product Description
Viking is developing small molecule inhibitors, including VK1430, of the enzyme diacylglycerol O-acyltransferase 1 (DGAT-1) for the potential treatment of metabolic disorders such as hypertriglyceridemia, NASH, obesity, and dyslipidemia. This program is in the Preclinical stage. (Sourced from: https://vikingtherapeutics.com/pipeline/other-pipeline-programs/vk1430/)
Mechanisms of Action: DGAT1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Viking
Company Location: Western America
Company CEO: Brian Lian
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Non-alcoholic Fatty Liver Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|